Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.76 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.76 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.62 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984692 | 0.90 | S1PR1 (0.74) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4984696 | 0.90 | S1PR1 (0.74) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4983240 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL4983228 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL14263147 | 0.85 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4983989 | 0.85 | S1PR1 (0.75) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL4629063 | 0.85 | S1PR1 (0.75) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL27701123 | 0.85 | S1PR1 (0.69) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL14263166 | 0.84 | S1PR1 (0.56) | S1PR1S1PR3S1PR4S1PR5PPARA | |
| SCHEMBL14263198 | 0.84 | S1PR1 (0.59) | S1PR1S1PR3S1PR4S1PR5PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885S1PR3 3/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.